Madrid are now so fed up with his injuries they're only looking for around £62-69m for him next summer.
The French forward instead opted to join Ligue 1 giants Paris Saint-Germain on loan, before making his move permanent in the summer of 2018.
The Welsh worldwide, 28, has suffered multiple injuries over the past 12 months, which has led to him playing in just nine of Real's 19 games in all competitions this season.
"If I am the manager for two or four more years, I would like to see him staying at Real Madrid". Of course. But his arrival could block the progress of Marcus Rashford, however with Mourinho favoring a 3-5-2 formation in recent weeks, Bale could easily line up in the No.10 role behind Romelu Lukaku and Rashford.
This is via a report from Spanish publication AS, who claim the Bernabeu have finally reached the rubicon with the Welsh winger.
Having publicly declared their frustration in the star, Real may now only see around half of what they could have raked in during the summer. Coleman has urged Bale to only stay at Real, if he is content with his life at the Spanish capital club.
GETTYReal Madrid want Kylian Mbappe to replace Gareth Bale
A report from AS in Spain says that Real Madrid have made a decision to offload Gareth Bale.
While that's a considerable drop on Bale's value last summer, Madrid are likely to still see value in the deal for a player that's missed almost 60% of matches since moving to Spain. "He comes with us, he is happy and we see an awesome player", the Mirror quoted Coleman as saying.
"He is finding that out and now and it is a shame and a loss for Madrid".
"Wherever he is not happy then he shouldn't be there".
"If he is happy in Madrid then fine, if he is not then he needs to go and play somewhere where he is happy".
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Quarterly EPS Analysis
You can get a sense of how sustainable that is by a levered free cash flow of $-217.87 Million over the past twelve months. Company's EPS for the past five years is valued at -31.8%, leading it to an EPS value of 0% for the next five years.